急性髓系白血病和高级别髓系肿瘤中可测量残留病复发与形态学复发的比较。 - Suppr

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.

作者信息

Shih Lauren, Othus Megan, Schonhoff Kelda, Shaw Carole, Appelbaum Jacob, Halpern Anna B, Becker Pamela S, Walter Roland B, Estey Elihu, Percival Mary-Elizabeth

机构信息

Department of Medicine, University of Washington, Seattle, WA, USA.

Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

出版信息

Leukemia. 2023 Sep;37(9):1912-1914. doi: 10.1038/s41375-023-01981-2. Epub 2023 Jul 31.

DOI:10.1038/s41375-023-01981-2

PMID:37524920

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10457180/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85cc/10457180/12b5ac6b6924/41375_2023_1981_Fig1_HTML.jpg

相似文献

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.急性髓系白血病和高级别髓系肿瘤中可测量残留病复发与形态学复发的比较。

Leukemia. 2023 Sep;37(9):1912-1914. doi: 10.1038/s41375-023-01981-2. Epub 2023 Jul 31.

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.对于大多数核心结合因子急性髓系白血病患者而言，可测量残留病监测所提供的提前期不足以预防形态学复发。

Haematologica. 2021 Jan 1;106(1):56-63. doi: 10.3324/haematol.2019.235721.

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.基于数字液滴 PCR 的移植前 NPM1 突变负担绝对定量可预测急性髓系白血病患者的复发。

Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22.

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.靶向 RNA 测序用于急性髓系白血病微小残留病的定量检测。

Haematologica. 2019 Feb;104(2):297-304. doi: 10.3324/haematol.2018.203133. Epub 2018 Aug 31.

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.成人急性髓系白血病异基因造血细胞移植后残留细胞遗传学异常和流式细胞术可测量残留病对结局的相对影响。

Haematologica. 2023 Feb 1;108(2):420-432. doi: 10.3324/haematol.2022.281585.

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.可测量残留病状态对接受异基因造血细胞移植的急性髓系白血病成人患者复发和生存预测准确性的贡献。

Haematologica. 2023 Jan 1;108(1):273-277. doi: 10.3324/haematol.2022.281631.

Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.纳入可测量的（“最小”）残留病导向治疗策略以优化成人急性髓系白血病的治疗结果。

Leuk Lymphoma. 2016 Jul;57(7):1527-33. doi: 10.3109/10428194.2016.1160085.

The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.最小杀伤：为什么定义和靶向可测量残留病是急性髓系白血病管理进一步进展的“必要条件”。

Blood Rev. 2020 Sep;43:100650. doi: 10.1016/j.blre.2019.100650. Epub 2019 Dec 20.

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.可测量的（“最小”）残留疾病（MRD）信息对成人急性髓系白血病复发和生存预测的影响。

Leukemia. 2016 Oct;30(10):2080-2083. doi: 10.1038/leu.2016.120. Epub 2016 May 2.

Measurable residual disease in pediatric acute myeloid leukemia: a systematic review.儿童急性髓系白血病的可测量残留病：系统评价。

Expert Rev Anticancer Ther. 2021 Apr;21(4):451-459. doi: 10.1080/14737140.2021.1860763. Epub 2021 Mar 11.

引用本文的文献

SOHO State of the Art Updates and Next Questions | Transplanting Hope: Managing Relapsed/Refractory AML.SOHO最新技术进展与后续问题 | 移植希望：复发性/难治性急性髓系白血病的管理

Clin Lymphoma Myeloma Leuk. 2025 Sep;25(9):615-624. doi: 10.1016/j.clml.2025.04.001. Epub 2025 Apr 8.

Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome.整合先进分析方法以评估影响高危骨髓增生异常综合征对去甲基化药物反应的表观遗传标记。

Mol Med. 2025 Feb 14;31(1):59. doi: 10.1186/s10020-025-01123-7.

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.初治强化疗后伴 CBF 或 NPM1 突变的急性髓系白血病患者的分子复发 - FILO 研究。

Leukemia. 2024 Sep;38(9):1949-1957. doi: 10.1038/s41375-024-02335-2. Epub 2024 Jul 17.

本文引用的文献

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议

Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.2021 年急性髓系白血病微小残留病更新：来自欧洲白血病网微小残留病工作组的共识文件。

Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626.

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.从 MDS 中区分 AML：固定的 blast 百分比可能不再是最佳选择。

Blood. 2022 Jan 20;139(3):323-332. doi: 10.1182/blood.2021011304.

Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.骨髓增生异常综合征伴原始细胞增多和继发性急性髓系白血病中髓系原始细胞计数和基因突变变异等位基因频率的比较。

Leuk Lymphoma. 2021 May;62(5):1226-1233. doi: 10.1080/10428194.2020.1861267. Epub 2020 Dec 19.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.急性髓系白血病的分子微小残留病。

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

Assessment of Minimal Residual Disease in Standard-Risk AML.标准风险 AML 中的微小残留病评估。

N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20.

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.急性髓系白血病的临床反应与微小残留病的关系及其对预后的影响。

J Clin Oncol. 2015 Apr 10;33(11):1258-64. doi: 10.1200/JCO.2014.58.3518. Epub 2015 Mar 2.

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.比较接受清髓性或非清髓性异基因造血细胞移植的处于首次完全缓解期的 AML 患者微小残留病作为预后指标的差异。

Leukemia. 2015 Jan;29(1):137-44. doi: 10.1038/leu.2014.173. Epub 2014 Jun 3.

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.在首次和第二次完全缓解的 AML 患者中，在清髓性异基因造血细胞移植前进行微小残留病检测的意义。

Blood. 2013 Sep 5;122(10):1813-21. doi: 10.1182/blood-2013-06-506725. Epub 2013 Jul 11.

9-color and 10-color flow cytometry in the clinical laboratory.临床实验室中的九色和十色流式细胞术。

Arch Pathol Lab Med. 2006 May;130(5):680-90. doi: 10.5858/2006-130-680-CACFCI.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献